Q3 Earnings Forecast for CryoPort Issued By Leerink Partnrs

Key Points

• Analysts at Leerink Partners increased their Q3 2025 earnings estimate for CryoPort to (-0.18) per share, and maintain a "Strong-Buy" rating on the stock.
• CryoPort recently reported Q2 earnings with a loss of (-0.29) EPS, missing estimates by (0.09), while revenue surpassed expectations at $45.45 million.
• Institutional investors own 92.90% of CryoPort’s stock, indicating strong confidence in the company's potential despite recent insider sales and other shifts in analyst ratings.

CryoPort, Inc. (NASDAQ:CYRX - Free Report) - Leerink Partnrs increased their Q3 2025 earnings estimates for shares of CryoPort in a note issued to investors on Wednesday, August 6th. Leerink Partnrs analyst P. Souda now forecasts that the company will earn ($0.18) per share for the quarter, up from their prior forecast of ($0.20). Leerink Partnrs currently has a "Strong-Buy" rating on the stock. The consensus estimate for CryoPort's current full-year earnings is ($0.99) per share. Leerink Partnrs also issued estimates for CryoPort's Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.84) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.19) EPS, Q3 2026 earnings at ($0.16) EPS and FY2026 earnings at ($0.67) EPS.

Several other equities research analysts have also weighed in on the company. Morgan Stanley decreased their price objective on CryoPort from $8.00 to $7.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. Leerink Partners upgraded CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 price objective on the stock in a research report on Wednesday. KeyCorp raised shares of CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 price target on the stock in a research note on Wednesday. Guggenheim reiterated a "buy" rating and issued a $10.00 price objective on shares of CryoPort in a research report on Wednesday, April 16th. Finally, Stephens assumed coverage on CryoPort in a report on Tuesday, July 22nd. They issued an "overweight" rating and a $13.00 price objective for the company. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $12.00.

CryoPort Stock Performance

Shares of NASDAQ CYRX traded down $0.64 during mid-day trading on Friday, reaching $7.56. 981,876 shares of the company's stock were exchanged, compared to its average volume of 974,076. The firm has a market capitalization of $379.06 million, a price-to-earnings ratio of 5.68 and a beta of 1.88. CryoPort has a 52 week low of $4.58 and a 52 week high of $9.66. The company has a debt-to-equity ratio of 0.51, a current ratio of 5.56 and a quick ratio of 5.24. The firm has a 50-day moving average price of $7.20 and a two-hundred day moving average price of $6.58.

CryoPort (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.09). The company had revenue of $45.45 million during the quarter, compared to analysts' expectations of $41.74 million. CryoPort had a net margin of 37.21% and a negative return on equity of 10.48%.

Insider Buying and Selling

In related news, Director Robert J. Hariri sold 12,500 shares of the business's stock in a transaction that occurred on Wednesday, May 28th. The stock was sold at an average price of $6.10, for a total value of $76,250.00. Following the completion of the sale, the director owned 8,061 shares in the company, valued at approximately $49,172.10. The trade was a 60.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jerrell Shelton sold 151,304 shares of the business's stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $6.81, for a total transaction of $1,030,380.24. Following the completion of the transaction, the chief executive officer directly owned 912,419 shares of the company's stock, valued at $6,213,573.39. This trade represents a 14.22% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 490,447 shares of company stock worth $3,337,198. Insiders own 10.00% of the company's stock.

Institutional Trading of CryoPort

Large investors have recently bought and sold shares of the stock. Intech Investment Management LLC boosted its holdings in CryoPort by 14.6% in the second quarter. Intech Investment Management LLC now owns 25,951 shares of the company's stock valued at $194,000 after purchasing an additional 3,305 shares during the last quarter. Creative Planning purchased a new stake in CryoPort during the 2nd quarter worth approximately $96,000. Geode Capital Management LLC lifted its holdings in CryoPort by 7.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,203,061 shares of the company's stock valued at $8,977,000 after purchasing an additional 87,418 shares in the last quarter. ProShare Advisors LLC acquired a new position in CryoPort during the second quarter worth about $75,000. Finally, Acadian Asset Management LLC raised its holdings in CryoPort by 14.4% in the 2nd quarter. Acadian Asset Management LLC now owns 548,842 shares of the company's stock valued at $4,090,000 after acquiring an additional 69,147 shares during the last quarter. Hedge funds and other institutional investors own 92.90% of the company's stock.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.